General interest

Our pick of Covid-related cross-sectional case control studies from the scientific press for October 2022

Read on for our highlighted selection of Covid-related Literature Reviews from the scientific press for October 2022.

Our highlighted selection of recent Covid-related case series or case reports from the scientific press for October 2022.

The EAN Guideline Production Group has developed a template for EAN guideline protocols, to facilitate production of high quality guidelines.

26th Conference of the European Society of Neurosonology and Cerebral Hemodynamics (ESNCH) October 14-16, 2022 Neurosonology 2022 will mark the return of fully presential meetings to the main worldwide event in Neurosonology, representing a unique opportunity to share knowledge. The… Continue Reading

Dr. Martin Rakusa speaks to Profs. Kristian Steen Frederiksen and Flavio Nobili, co-chairs of the EAN Scientific Panel on Dementia and Cognitive Disorders.

In summer 2022 EAN introduced a new membership benefit for Student Members: the option to join the EAN Scientific & Coordinating Panels.

Our highlighted selection of recent Covid-related case series or case reports from the scientific press for September 2022.

Our editors' pick of recent Covid-related cross-sectional case control studies from the scientific press for September 2022.

This week, the European Brain Council responded to the European Commission’s Call for Proposals on 2022 Thematic Networks, which invites health stakeholders to submit proposals for a new cycle of Thematic Networks, organised under the framework of the EU Health… Continue Reading

A joint session between the International Parkinson and Movement Disorder Society and the EAN will be held on 16 September, during the MDS Congress.

For the 9th Annual Congress of the European Academy of Neurology on July 1-4 we are heading to the grand and beautiful city of Budapest, Hungary, right in the heart of Europe.

New EAN Education Committee Chair, Irena Retorova, introduces herself with an overview of recent and upcoming EAN educational initiatives.

This month we have selected two phase-2 trials investigating α-synuclein-binding antibodies as potential disease-modifying treatment of Parkinson’s disease.

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.